Detection of a Platelet-Agglutinating Factor in Thrombotic Thrombocytopenic Purpura
- JOHN G. KELTON, M.D.;
- JANE MOORE, A.R.T.;
- AURELIO SANTOS, R.T.; and
- DAVID SHERIDAN, M.D.
Abstract
A sensitive and specific test was used to identify a platelet-agglutinating factor in sera from patients with thrombotic thrombocytopenic purpura. Serum from patients plus a preparation rich in large multimers of factor VIII: von Willebrand factor were added to target platelets, and agglutination occurred in 41 of 48 samples. Edetic acid, heparin, or heating, but not aspirin, monomeric IgG, or dansylarginine N-(3-ethyl-1,5-pentanediyl)amide inhibited the platelet-agglutinating factor. In-vitro agglutination requires the presence of a platelet-agglutinating factor and large multimers of von Willebrand factor. High concentrations of either component lowers the amount of the other required for platelet agglutination. Some patients may be more susceptible to the agglutinating factor because of a congenital or acquired abnormality in processing unusually large multimers of von Willebrand factor or because of infections or inflammatory disorders that lead to increased synthesis of large multimers of von Willebrand factor.
Article and Author Information
-
▸From the Departments of Medicine and Pathology, McMaster University Medical Centre; and the Canadian Red Cross Blood Transfusion Service, Hamilton Centre; Hamilton, Ontario, Canada.
-
Grant support: by a grant from the Ontario Heart Foundation. Dr. Kelton is a Canadian Heart Foundation Scholar.
-
▸Requests for reprints should be addressed to John G. Kelton, M.D.; Room 2N34, McMaster University Medical Centre, Box 2000, Station A; Hamilton, Ontario, Canada L8N 3Z5.
- ©1984 American College of Physicians
RSS Feeds









